WO2017220845A1 - Composiciones para el tratamiento de estrías y úlceras de origen isquémico - Google Patents
Composiciones para el tratamiento de estrías y úlceras de origen isquémico Download PDFInfo
- Publication number
- WO2017220845A1 WO2017220845A1 PCT/ES2017/070460 ES2017070460W WO2017220845A1 WO 2017220845 A1 WO2017220845 A1 WO 2017220845A1 ES 2017070460 W ES2017070460 W ES 2017070460W WO 2017220845 A1 WO2017220845 A1 WO 2017220845A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- optionally substituted
- branched
- treatment
- compound
- composition
- Prior art date
Links
- HSUGRBWQSSZJOP-UHFFFAOYSA-N CC(OC(C(c(cc1)ccc1OC)Sc1ccccc1N1CCN(C)C)C1=O)=O Chemical compound CC(OC(C(c(cc1)ccc1OC)Sc1ccccc1N1CCN(C)C)C1=O)=O HSUGRBWQSSZJOP-UHFFFAOYSA-N 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- the present invention is within the field of medicine and pharmacy, and refers to the use of benzothiazepines, their pharmaceutically acceptable salts, solvates and hydrates in the preparation of medicaments for the treatment of stretch marks and ulcers, preferably ulcers of the skin and specifically of ulcers of ischemic origin.
- the colorimetric evaluation of SD by high resolution epiluminescence has identified four different types: alba striae alba, striae rubra, striae caerulea, and striae nigra.
- the direct and indirect influences of melanocyte mechanobiology seem to have an important effect on the different colors of SD (Pierard & Hermans 2006. JEADV 20: 282-7).
- the histology of the stretch marks is that of a scar, and the development of SD has been compared with that of wound healing or scar formation. In the early stages inflammatory changes can be conspicuous, but later the epidermis is thin and flattened. Recent SDs show a deep and superficial perivascular lymphocytic infiltration around the venules.
- the collagen bands in the upper third of the reticular dermis are stretched and aligned parallel to the surface of the skin.
- there is a thinning of the epidermis due to flattening of the epithelial ridges and the loss of collagen and elastin.
- the different hypotheses about the development of SD in the literature are: 1.- The infection leads to the release of striatoxin that damages the tissues in a toxic microbial form. 2. - The mechanical effect of stretching, which can lead to the breakdown of the connective tissue structure (For example, pregnancy, obesity, weightlifting).
- ulcerations occur in the lower extremities, with a global prevalence of between 0.18 and 2%, and in patients over 65 years of age, 5%. Most ulcerations in the lower extremities are venous, around 70%. Those of the arterial type, of ischemic origin in general, represent between 10 and 30%. According to other sources, the prevalence of arterial ulcers in people over 65 years is between 8 and 1 1%. In subjects with less than 60 years, the prevalence is around 2%.
- ulcers of ischemic origin can be due to several factors: they can appear as a result of an affectation of the cutaneous vasculature, which in turn can be due to another underlying disease (chronic venous insufficiency, atherosclerosis, diabetes mellitus, vasculitis, thrombophilia , systemic sclerosis, etc.); on other occasions, they may be the result of medical or surgical treatment.
- ischemic ulcer occurs at the same time as a treatment applied to treat another patient's disease, doctors may be forced to decide whether to stop the treatment of this other underlying disease to avoid ulcers, with All the risks and the problems involved.
- ulcers of ischemic origin For the treatment of ulcers of ischemic origin, care for more general wounds is currently being used, mainly orally. Medications targeting blood pressure, cholesterol and diabetes are usually prescribed, along with aspirin or other anticoagulant or antiplatelet medications. In some cases, an angiogram may be performed, a test in which contrast dye is injected into the blood vessels and special x-rays are taken to identify blockages. In others, bypass surgery may be necessary to restore blood flow. It should be noted that the appearance of ulcers of ischemic origin can occur both in more common and widespread pathologies, and with greater prevalence (case of perniosis), as in more serious pathologies, (for example, complications of diabetes). Here are some examples.
- Perniosis erythema pernio, more commonly chilblains
- Perniosis can lead to ulcers of ischemic origin.
- Perniosis consists in the development of inflammatory, erythematous and often pruritic lesions, of acral location, after contact with the cold. Complications can be local in the form of painful fissures, superinfection or the formation of true ulcers.
- the treatment for perniosis focuses mainly on measures to minimize exposure to cold, reserving drug therapy for patients who do not improve with these interventions. Patients with perniosis are advised to keep the affected area warm by wearing properly insulated clothing, gloves or shoes, and avoid exposure to the cold without adequate protection. It is also urged to quit smoking, due to the harmful effect of smoking on vascular disease. Data on the efficacy of other interventions for perniosis are limited. Topical and cortical corti and nifedipine (indication for cardiovascular disease) are among the most commonly used drug therapies. In clinical practice, corticosteroids are sometimes prescribed.
- Diabetes mellitus is another disease in which ulcers may appear, such as diabetic foot ulcers. Some estimates predict that the number of diabetics will increase to more than half a billion in 2035, according to the International Diabetes Federation. Susceptibility to foot ulcers for diabetics varies with age, sex, health and social factors. Estimates of the annual incidence of diabetic foot ulcers vary from 2.5 to 10.7 percent of diabetic patients in developed economies. The incidence may be higher in poor countries due to lack of education, advanced therapies or comprehensive health infrastructure. More severe lower limb ulcers may require amputations of the limbs. Amputations that arise from complications and improper management are expensive. In the United States, limb amputations cost approximately $ 70,000 on average, $ 30,000 annually for the entire health system. In the EU, amputations can increase the cost of treating diabetic foot ulcers to more than € 50,000 ($ 56,687) per case.
- Systemic sclerosis (or scleroderma) is an autoimmune disease that involves the accumulation of scar-like tissue in the skin and other parts of the body. It also damages the cells that line the walls of small arteries. The overall prevalence of this disease is estimated at 242 cases per million inhabitants per year, and its incidence varies between 0.6 and 19 cases per million inhabitants per year, and affects about three times more women than men.
- a first aspect of the present invention relates to the use of a compound of general formula (I):
- Formula (I) or any of its salts preferably any pharmaceutically acceptable salt, esters, tautomers, polymorphs, pharmaceutically acceptable hydrates, or an isomer, prodrugs, derivatives, solvates or the like, or any combination thereof, hereinafter composed of the invention, in the preparation of a medicament for the prevention, improvement, relief and / or treatment of stretch marks, where:
- R 5 is independently selected from the group consisting of hydrogen, optionally substituted straight or branched chain CC 5 , straight chain C 2 -C 5 alkenyl or optionally substituted branched alkenyl, C 2 -C 5 straight chain or branched alkenyl optionally substituted, C 3 -C 7 cycloalkyl, and C5-C1 0 cycloalkenyl, aryl or optionally substituted heteroaryl; or two R 5 and X may form C 3 -C 7 cycloalkyl, heterocyclic ring, aryl, or optionally substituted heteroaryl.
- each R 6 is independently selected from the group consisting of hydrogen, CC 5 straight or branched chain optionally substituted alkyl, alkenyl C 2 -C 5 straight or branched chain optionally substituted alkynyl , C 2 -C 5 chain linear or branched optionally substituted, C 3 - cycloalkyl
- the compound is Diltiazem, of formula (II), or cis - (+) - [2- (2-dimethylaminoethyl) -5- (4-methoxyphenyl) -3-oxo -6-tia-2- azabicyclo [5.4.0] undeca-7,9, 11-trien-4-yl] ethanoate, CAS number 42399-41-7
- a second aspect relates to the use of the compound of the invention, or any of its salts, preferably any pharmaceutically acceptable salt, esters, tautomers, polymorphs, pharmaceutically acceptable hydrates, or an isomer, prodrugs, derivatives, solvates or the like, or any of their combinations, in the elaboration of a medicine for the prevention, improvement, relief, and / or treatment of skin ulcers.
- the compound of the invention refers to the compound of the invention or any of its salts, preferably any pharmaceutically acceptable salt, esters, tautomers, polymorphs, pharmaceutically acceptable hydrates, or an isomer, prodrugs, derivatives, solvates or the like, or any combination thereof, for its use in the prevention, improvement, relief and / or treatment of skin ulcers.
- skin ulcers are ischemic ulcers. More preferably they are cutaneous ulcers of ischemic origin of difficult clinical management.
- the composition of the invention is used for the treatment of diseases that occur with the production of ischemic ulcers. More preferably the disease that is caused by the production of ischemic ulcers is selected from: perniosis, bullous epidermolysis, venous insufficiency, vasculitis, collagenopathies (such as, but not limited to, systemic lupus erythematosus and systemic scleroderma), suture dehiscence ulcers, situations of cutaneous ischemic risk after surgery (flaps or skin grafts), skin ulcers due to diabetic microangiopathy (diabetic foot), or any combination thereof.
- perniosis bullous epidermolysis, venous insufficiency, vasculitis, collagenopathies (such as, but not limited to, systemic lupus erythematosus and systemic scleroderma), suture dehiscence ulcers, situations of cutaneous ischemic risk after surgery (flaps or skin
- a third aspect relates to the use of a composition, hereinafter composition of the invention, comprising at least one compound of the invention, or a tautomer, a pharmaceutically acceptable salt, a derivative or a prodrug thereof, in the preparation of a medicine for the prevention, relief, improvement and / or treatment of stretch marks.
- a composition hereinafter composition of the invention, comprising at least one compound of the invention, or a tautomer, a pharmaceutically acceptable salt, a derivative or a prodrug thereof, in the preparation of a medicine for the prevention, relief, improvement and / or treatment of stretch marks.
- it refers to the composition of the invention, for use in the prevention, relief, improvement and / or treatment of stretch marks.
- the composition of the invention is a pharmaceutical composition.
- the composition of the invention further comprises a pharmaceutically acceptable carrier or carrier, or a pharmaceutically acceptable carrier and / or carrier.
- the composition of the invention is a cosmetic composition.
- a fourth aspect refers to the use of the composition of the invention in the preparation of a medicament for the prevention, relief, improvement and / or treatment of skin ulcers.
- a medicament for the prevention, relief, improvement and / or treatment of skin ulcers.
- skin ulcers are ischemic ulcers. More preferably they are cutaneous ulcers of ischemic origin of difficult clinical management.
- the composition of the invention is used for the treatment of diseases that occur with the production of ischemic ulcers.
- the disease that occurs with the production of ischemic ulcers is selected from: perniosis, bullous epidermolysis, venous insufficiency, vasculitis, collagenopathies (such as, but not limited to, systemic lupus erythematosus and systemic scleroderma), dehiscence ulcers of suture, situations of cutaneous ischemic risk after surgery (flaps or skin grafts), skin ulcers due to diabetic microangiopathy (diabetic foot), or any combination thereof.
- perniosis bullous epidermolysis, venous insufficiency, vasculitis, collagenopathies (such as, but not limited to, systemic lupus erythematosus and systemic scleroderma), dehiscence ulcers of suture, situations of cutaneous ischemic risk after surgery (flaps or skin grafts), skin ulcers due to diabetic microangiopathy (diabetic foot), or any combination
- FIG. 1 Ulcers on the skin in the abdomen that involve stretch marks (Fig. 1 a) and ulcer of the healed skin after treatment with topical diltiazem (Fig. 1 b).
- Fig. 2A Patient with perniosis (Fig. 2A).
- FIG. 3 Patient with epidermolysis bullosa with chronic ulcer of 12 months evolution (Fig. 3A). Clinical response after 4 weeks of treatment with diltiazem every 12 hours (Fig. 3B). Fig. 4. Clinical response of vascular torpid leg ulcer.
- FIG. 5 Suture dehiscence after abdominal surgery (Fig. 5A). Image of dehiscence with a deep ulcer with congestion at the edges, after three weeks of cures with chlorhexidine and then diltiazem 2% cream every 12 hours (Fig. 5B).
- a first aspect of the present invention relates to the use of a compound of general formula (I):
- Formula (I) or any of its salts preferably any pharmaceutically acceptable salt, esters, amides, tautomers, polymorphs, pharmaceutically acceptable hydrates, or an isomer, prodrugs, derivatives, solvates or the like, or any combination thereof, hereinafter compound of the invention , in the preparation of a medicine for the prevention, improvement, relief and / or treatment of stretch marks, where:
- X is selected from the group consisting of oxygen, sulfur, NR 5 , C (R 5 ) 2 ,
- R 5 is independently selected from the group consisting of hydrogen, optionally substituted straight or branched chain CC 5 , straight chain C 2 -C 5 alkenyl or optionally substituted branched alkenyl, C 2 -C 5 straight chain or branched alkenyl optionally substituted, C 3 -C 7 cycloalkyl, and C5-C1 0 cycloalkenyl, aryl or optionally substituted heteroaryl; or two R 5 and X may form C 3 -C 7 cycloalkyl, heterocyclic ring, aryl, or optionally substituted heteroaryl.
- stretch marks refers to irregular areas of skin that resemble bands, stripes or lines. Stretch marks (or stretch marks) are seen when a person grows, gains weight quickly or has certain conditions or diseases. Stretch marks can appear when there is a rapid stretching of the skin. Often, they are observed when a woman's abdomen enlarges during pregnancy. They can also occur in children who have quickly become obese. They can also occur in boys and girls during rapid growth at puberty. The most common location of stretch marks is found in the breasts, hips, thighs, buttocks, abdomen and sides. Stretch marks appear in the form of parallel lines of reddish, shiny and thin skin that over time become whitish and scar-like.
- Stretch marks may be slightly sunken and have a different texture from normal skin. They can also occur as a result of abnormal collagen formation or as a result of medicines or chemicals that interfere with the formation of it. In the same way, they may be associated with prolonged use of cortisone compounds, diabetes, Cushing's disease and the postpartum period. Causes may include any of the following: Cushing syndrome, Ehlers-Danlos syndrome, pregnancy, puberty, obesity and / or excessive use of cortisone-based skin creams (U.S. National Library of Medicine).
- the compound is Diltiazem, of formula (II), or cis - (+) - [2- (2-dimethylaminoethyl) -5- (4-methoxyphenyl) -3-oxo -6-tia-2- azabicyclo [5.4.0] undeca-7,9, 11-trien-4-yl] ethanoate, CAS number 42399-41-7
- diazem is not limited to the hydrochloride salt, but includes any and all salts other than the hydrochloride salt.
- “diltiazem” includes the free base compound.
- the scope of the present invention also includes the use of other diltiazem diastereomers, including the isomer (2R, 3S), the isomer (2S, 3R), and the isomer (2R, 3R).
- the scope of the present invention also includes the use of mixtures of any and all of the mentioned isomers, including racemic and optically inactive mixtures.
- a second aspect relates to the use of the compound of the invention, or any of its salts, preferably any pharmaceutically acceptable salt, esters, amides, tautomers, polymorphs, pharmaceutically acceptable hydrates, or an isomer, prodrugs, derivatives, solvates or the like, or any of its combinations, in the elaboration of a medicine for the prevention, improvement, relief, and / or treatment of skin ulcers.
- it refers to the compound of the invention or any of its salts, preferably any pharmaceutically acceptable salt, esters, amides, tautomers, polymorphs, pharmaceutically acceptable hydrates, or an isomer, prodrugs, derivatives, solvates or the like, or any combination thereof. , for use in the prevention, improvement, relief and / or treatment of skin ulcers.
- ischemic ulcers of ischemic origin refers to ulcers (wounds) that occur on the skin when there is poor blood flow. Poor blood flow causes cell death and tissue damage. Most ischemic ulcers occur in the feet and legs. They are usually slow wounds to heal. Clogged arteries (atherosclerosis) are the most common cause of ischemic ulcers: • Clogged arteries prevent healthy blood flow to the legs. This means that the tissues in the legs do not receive enough nutrients and oxygen.
- ischemic ulcers are secondary to arterial insufficiency, venous insufficiency, defects in microcirculation (such as in diabetes, rheumatic diseases such as scleroderma, etc.), primary or secondary thrombophilia or hypercoagulability states (due to tumors, rheumatologic diseases such as systemic lupus, etc.), or they may be caused by iatrogenesis (secondary to antiangiogenic medical treatments or surgical or invasive procedures, such as catheterizations, etc.
- skin ulcers are ischemic ulcers. More preferably they are cutaneous ulcers of ischemic origin of difficult clinical management.
- the composition of the invention is used for the treatment of diseases that occur with the production of ischemic ulcers. More preferably the disease that occurs with the production of ischemic ulcers is selected from: perniosis, bullous epidermolysis, venous insufficiency, vasculitis, collagenopathies (such as, but not limited to, systemic lupus erythematosus and systemic scleroderma), dehiscence ulcers of suture, situations of cutaneous ischemic risk after surgery (flaps or skin grafts), skin ulcers due to diabetic microangiopathy (diabetic foot), or any combination thereof.
- perniosis bullous epidermolysis, venous insufficiency, vasculitis, collagenopathies (such as, but not limited to, systemic lupus erythematosus and systemic scleroderma), dehiscence ulcers of suture, situations of cutaneous ischemic risk after surgery (flaps or skin
- a third aspect relates to the use of a composition, hereinafter composition of the invention, comprising at least one compound of the invention, or a tautomer, a pharmaceutically acceptable salt, a derivative or a prodrug thereof, in the preparation of a medicine for the prevention, relief, improvement and / or treatment of stretch marks.
- a composition hereinafter composition of the invention, comprising at least one compound of the invention, or a tautomer, a pharmaceutically acceptable salt, a derivative or a prodrug thereof, in the preparation of a medicine for the prevention, relief, improvement and / or treatment of stretch marks.
- the composition of the invention comprises as the only active ingredient the compound of the invention, although it may comprise other pharmaceutically acceptable excipients and carriers.
- composition of the invention is a pharmaceutical composition.
- composition of the invention further comprises a pharmaceutically acceptable carrier or carrier, or a pharmaceutically acceptable carrier and / or carrier.
- the composition of the invention is a cosmetic composition.
- the cosmetic composition may comprise cosmetically acceptable excipients.
- a fourth aspect refers to the use of the composition of the invention in the preparation of a medicament for the prevention, relief, improvement and / or treatment of skin ulcers. Alternatively, for use in the prevention, relief, improvement and / or treatment of skin ulcers.
- skin ulcers are ischemic ulcers. More preferably they are cutaneous ulcers of ischemic origin of difficult clinical management.
- the composition of the invention is used for the treatment of diseases that occur with the production of ischemic ulcers. More preferably the disease that occurs with the production of ischemic ulcers is selected from: perniosis, bullous epidermolysis, venous insufficiency, vasculitis, collagenopathies (such as, but not limited to, systemic lupus erythematosus and systemic scleroderma), dehiscence ulcers of suture, situations of cutaneous ischemic risk after surgery (flaps or skin grafts), skin ulcers due to diabetic microangiopathy (diabetic foot), or any combination thereof.
- perniosis bullous epidermolysis, venous insufficiency, vasculitis, collagenopathies (such as, but not limited to, systemic lupus erythematosus and systemic scleroderma), dehiscence ulcers of suture, situations of cutaneous ischemic risk after surgery (flaps or skin
- composition of the invention comprises as the only active ingredient the compound of the invention, although it may comprise other pharmaceutically acceptable excipients and carriers.
- composition of the invention is a pharmaceutical composition.
- composition of the invention further comprises a pharmaceutically acceptable carrier or carrier, or a pharmaceutically acceptable carrier and / or carrier.
- the composition of the invention is a cosmetic composition.
- the cosmetic composition may comprise cosmetically acceptable excipients.
- cosmetic composition of the invention for use in skin atrophies.
- skin atrophies are stretch marks. More preferably the stretch marks are selected from albicating stretch marks, atrophic stretch marks and stretch marks.
- the compounds of the present invention represented by formula (I) and / or (II) may include isomers, depending on the presence of multiple bonds, including optical isomers or enantiomers, depending on the presence of chiral centers.
- the individual isomers, enantiomers or diastereoisomers and mixtures thereof fall within the scope of the present invention, that is, the term isomer also refers to any mixture of isomers, such as diastereomers, racemic, etc., even their optically isomers. assets or mixtures in different proportions thereof.
- the individual enantiomers or diastereoisomers, as well as mixtures thereof, can be separated by conventional techniques.
- prodrugs of the compounds of formula (I) and / or (II) include any derivative of a compound of formula (I) and / or (II) - for example and not limited to: esters (including esters of carboxylic acids, amino acid esters, phosphate esters, sulphonate esters of metal salts, etc.), carbamates, amides, etc- that when administered to an individual can be transformed directly or indirectly into said compound of formula (I) and / or (II) in the mentioned individual.
- said derivative is a compound that increases the bioavailability of the compound of formula (I) and / or (II) when administered to an individual or that enhances the release of the compound of formula (I) and / or (II) in a biological compartment
- the nature of said derivative is not critical as long as it can be administered to an individual and provides the compound of formula (I) in a biological compartment of an individual.
- the preparation of said prodrug can be carried out by conventional methods known to those skilled in the art.
- derivative includes both pharmaceutically acceptable compounds, that is, derivatives of the compound of formula (I) and / or (II) that can be used in the preparation of a medicament or food compositions, as pharmaceutically unacceptable derivatives, since these may be useful in the preparation of pharmaceutically acceptable derivatives.
- the compounds of the invention may be in crystalline form as free compounds or as solvates.
- solvate includes both pharmaceutically acceptable solvates, that is, solvates of the compound of formula (I) and / or (II) that can be used in the manufacture of a medicament, as pharmaceutically acceptable solvates, which may be useful in the preparation of pharmaceutically acceptable solvates or salts.
- pharmaceutically acceptable solvate is not critical as long as it is pharmaceutically acceptable.
- the solvate is a hydrate.
- Solvates can be obtained by conventional solvation methods known to those skilled in the art.
- the compounds of formula (I) and / or (II), their salts, prodrugs or solvates will preferably be in a pharmaceutically acceptable or substantially pure form, that is, having a level of purity pharmaceutically acceptable excluding normal pharmaceutical additives such as diluents and carriers, and not including material considered toxic at normal dosage levels.
- the purity levels for the active ingredient are preferably greater than 50%, more preferably greater than 70%, and still more preferably greater than 90%. In a preferred embodiment, they are greater than 95% of the compound of formula (I), or of its salts, solvates or prodrugs.
- compositions of the invention are the adjuvants and vehicles known to those skilled in the art and commonly used in the elaboration of therapeutic compositions.
- therapeutically effective amount refers to the amount of the agent or compound capable of developing the therapeutic action determined by its pharmacological properties, calculated to produce the desired effect and, in general, will be determined, among other causes, due to the characteristics of the compounds, including the age, condition of the patient, the severity of the alteration or disorder, and the route and frequency of administration.
- the compositions of the invention comprise the compound of the invention in a proportion of between 0.1% and 10%, more preferably, between 0.5% and 7.5%, even more preferably between 1% and 5%, and even more preferably between 1.5% and 2.5% by weight.
- the proportion of the compound of the invention in the composition of the invention is approximately 2% in weight. More preferably, the compound of the invention is diltiazem.
- the composition of the invention comprises, as the only active ingredient, the compound of the invention, although it may comprise pharmaceutically acceptable excipients and / or carriers. More preferably the compound of the invention is in the concentrations described above, and even more preferably the compound of the invention is diltiazem.
- the compounds described in the present invention, their salts, prodrugs and / or solvates as well as the pharmaceutical compositions containing them can be used together with other drugs, or additional active ingredients, to provide a combination therapy.
- Said additional drugs may be part of the same pharmaceutical or cosmetic composition or, alternatively, they may be provided in the form of a separate composition for simultaneous or non-simultaneous administration to the pharmaceutical or cosmetic composition, which comprises a compound of formula (I) or of formula (II), or a salt, prodrug or solvate thereof. Therefore, in another preferred embodiment, the pharmaceutical or cosmetic composition further comprises another active ingredient.
- this active ingredient is moisturizing and / or firming.
- the moisturizing active ingredient may be formulated with wetting active ingredients, molecules with occlusive capacity and / or lipids.
- the firming active ingredients are characterized by including in their formulation elastin and collagen, in addition to plant extracts with various functions: regenerating, tensing and stimulating proteosynthesis.
- the formulations of the firming cosmetics are usually composed mainly of active ingredients that regenerate the connective tissue and tensile assets, in addition to the aforementioned moisturizing active ingredients.
- the active ingredient is selected from the list consisting of: Glycerin, Propylene Glycol, sorbitol, low molecular weight polyethylene glycols (PEG 400), Acetamide derivatives, Glucose ethers, Betaine, Saccharides isomerate, beeswax, lanolin , Vaseline, Analogues of the Natural Moisturizing Factor (pyrrolidinecarboxylic acid, urea, lactic acid / sodium lactate, sugars, allantoin), Lactic salts Collagen, Elastin, Hyaluronic Acid, Chitosan, Galactomannan, Silicon, Echinacea angustifolia extract, Mimosa Teuiflora tecouiflora unsaponifiable avocado oil and shea butter, Centella asiatica and / or Vitamin A or retinol and / or vitamin E
- active substance means any component that potentially provides a pharmacological activity or other different effect on the diagnosis, cure, mitigation, treatment, or prevention of a disease, or that affects the structure or function of the body of man or other animals. He term includes those components that promote a chemical change in the preparation of the drug and are present therein in a modified form intended to provide the specific activity or effect.
- PHARMACEUTICAL FORMS OF THE INVENTION Another aspect of the invention relates to a pharmaceutical form, hereinafter pharmaceutical form of the invention, comprising the compound of the invention or the composition of the invention.
- pharmaceutical form means the mixture of one or more active ingredients with or without additives that have physical characteristics for proper dosage, preservation, administration and bioavailability.
- compositions and pharmaceutical forms of the invention are suitable for topical administration.
- Possible forms for topical administration are, but are not limited to, plaster, ointment, paste, cream, solution, suspension, emulsion, lotion, liniment, gel, hydrogel, hydrocolloid, foam, powder, or any combination thereof.
- a "plaster” or “patch” is a pharmaceutical form that consists of a solid or semi-solid form that contains the active ingredient or additives, spread on a cloth, plastic or adhesive tape, which serves as a support and protection, in addition to having an occlusive effect and macerating action that also allows direct contact with the skin and softens with body temperature.
- an “ointment” or “ointment” is a pharmaceutical form consisting of a soft consistency preparation that contains the active ingredient or additives incorporated into an appropriate base that gives it mass and consistency. It adheres and is applied to the skin and mucous membranes.
- This base can be liposoluble or water soluble, it is generally anhydrous or with a maximum of 20 percent water. It is also called hydrophilic ointment when it contains a washable or removable base with water.
- a “paste” is a pharmaceutical form consisting of a semi-solid form containing the active ingredient or additives, made from a high concentration of insoluble powders (20 to 50 percent), in fatty or aqueous, absorbent or weak abrasives combined with soaps.
- a “cream” is a pharmaceutical form consisting of a liquid or semi-solid preparation that contains the active ingredient or additives necessary to obtain an emulsion, generally oil in water, with a water content greater than 20 percent.
- a “solution” is a pharmaceutical form that consists of a liquid, transparent and homogeneous preparation, obtained by dissolving it or the active ingredients and additives in water, and which is used for external or internal use. In the case of injectable, ophthalmic and otic solutions they must be sterile solutions.
- solution includes the solutions.
- An “emulsion” is a pharmaceutical form consisting of a heterogeneous system, generally consisting of two liquids not miscible with each other; in which the dispersed phase is composed of small globules distributed in the vehicle in which they are immiscible.
- the dispersed phase is also known as internal and the dispersion medium is known as the external or continuous phase.
- the active ingredient or additives may be in the external or internal phase.
- a “lotion” is a pharmaceutical form that can be presented as a solution, suspension or emulsion, which contains the active ingredient (s) and additives, and whose dispersing agent is predominantly water.
- a “liniment” is a pharmaceutical form that consists of a liquid presentation, solution or emulsion that contains the active ingredient or additives whose vehicle is aqueous, alcoholic or oily.
- a “jelly” is a pharmaceutical form that consists of a semi-solid colloid that contains the active substance or additives, whose water-soluble base is usually made up of gums such as tragacanth, other bases used are: glycerin, pectin, alginates , boroglycerinated compounds, synthetic derivatives or natural substances such as carboxymethyl cellulose.
- a “gel” is a pharmaceutical form consisting of semi-solid preparation, which contains the active ingredient or additives, solid in a liquid that can be water, alcohol or oil, such that a network of particles trapped in the liquid phase.
- Hydrogels are colloidal systems with a solid appearance such as heat coagulated albumin, gelatin gelled by cooling, etc.
- One of the properties of Hydrogels is to swell and increase in volume by absorption of water and dissolved substances, common property to all tissues of organisms formed by colloidal materials.
- Colloids are materials formed by a dispersed phase (matrix) and a dispersing phase (filler). When the dispersing phase is water, it is called “hydrocolloid.” They are characterized in that they can coagulate (pass from solution to solid gel) if the dispersed phase is abundant, and flocculate (pass from gel to solution) when the dispersed phase is scarce.
- the pharmaceutical form of the invention preferably comprises the compound of the invention in a proportion of between 0.1% and 10%, more preferably, between 0.5% and 7.5%, even more preferably between 1% and 5%, and even more preferably between 1.5% and 2.5% (by weight).
- the proportion of the compound of the invention in the composition of the invention is about 2% (by weight). More preferably, the compound of the invention is diltiazem.
- the composition of the invention comprises, as the only active ingredient, the compound of the invention, although it may comprise pharmaceutically acceptable excipients and / or carriers. More preferably the compound of the invention is in the concentrations described above, and even more preferably the compound of the invention is diltiazem.
- the aforementioned formulations can be prepared using conventional methods, such as those described in the Pharmacopoeias of different countries and in other reference texts.
- medication refers to any substance used for prevention, diagnosis, relief, treatment or cure of diseases in man and animals.
- administration of the compounds, compositions or pharmaceutical forms of the present invention can be performed by any suitable method, such as intravenous infusion and oral, topical or parenteral routes. Topical administration is preferred for the convenience of patients and for the nature of the diseases to be treated.
- the amount administered of a compound of the present invention will depend on the relative efficacy of the compound chosen, the severity of the disease to be treated and the weight of the patient. However, the compounds of this invention will be administered one or more times a day, for example 1, 2, 3 or 4 times daily, with a total dose between 0.1 and 1000 mg / kg / day. It is important to keep in mind that it may be necessary to introduce variations in the dose, depending on the age and condition of the patient, as well as modifications in the route of administration.
- the compounds and compositions of the present invention can be used together with other medicaments in combination therapies.
- the other drugs may be part of the same composition or of a different composition, for administration at the same time or at different times.
- the patient was treated with 2% diltiazem cream twice daily and wound care with polyurethane dressing.
- the response to treatment with diltiazem was excellent.
- the ulcers healed completely in four weeks ( Figure 1b), without the need to suspend bevacizumab.
- Figure 1b After the suspension of topical diltiazem developed a new ulcerated lesion located in the stretch marks that was resolved with reintroduction again.
- the patient continues on treatment with bevacizumab, and achieved radiological stability and remains without ulcers.
- Example 2 Patient with perniosis in hands for years with the appearance of outbreaks with pain and pruritus in times of cold. Go to the consultation for perniotic lesions on hands with numerous painful, cracked, erythematoviolous lesions. Treatment with 2% diltiazem cream is started every 12 hours and a complete resolution of the lesions and symptoms is seen after three days of treatment.
- Example 3 3-year-old male patient with recessive dystrophic epidermolysis bullosa presenting a chronic ulcer in the pectoral area of more than a year of evolution with exudation and daily pain. Treatment with diltiazem cream 2% cream is started every 12 hours with good tolerance and partial response after 4 weeks of treatment.
- Example 4 Patient with systemic lupus erythematosus who has had a vascular torpid leg ulcer for years that does not yield with normal cures. Treatment with diltiazem 2% cream is started after six months, obtaining a complete resolution of the ulcer.
- Example 5 Two-week-old neonata presenting a suture dehiscence after abdominal surgery of a lymphatic malformation. After 7 days of evolution without improvement of dehiscence with usual cures, treatment with 2% diltiazem cream is started every 12 hours until a complete resolution of the dehiscence is obtained after 3 weeks of treatment.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Birds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/312,898 US10960011B2 (en) | 2016-06-23 | 2017-06-23 | Compositions for the treatment of ischemic ulcers and stretch marks |
CN201780052257.3A CN109641001A (zh) | 2016-06-23 | 2017-06-23 | 用于治疗缺血性溃疡和伸展疤痕的组合物 |
EP17814811.0A EP3476394A4 (en) | 2016-06-23 | 2017-06-23 | COMPOSITIONS FOR TREATING ISCHEMIC ULZERA AND STRETCH STRIPS |
MX2019000006A MX2019000006A (es) | 2016-06-23 | 2017-06-23 | Composiciones para el tratamiento de estrias y ulceras de origen isquemico. |
JP2018567607A JP2019518780A (ja) | 2016-06-23 | 2017-06-23 | 虚血性潰瘍及び伸展線の処置用組成物 |
CA3065893A CA3065893A1 (en) | 2016-06-23 | 2017-06-23 | Compositions for the treatment of ischemic ulcers and stretch marks |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201630856 | 2016-06-23 | ||
ESP201630856 | 2016-06-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017220845A1 true WO2017220845A1 (es) | 2017-12-28 |
Family
ID=60783358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2017/070460 WO2017220845A1 (es) | 2016-06-23 | 2017-06-23 | Composiciones para el tratamiento de estrías y úlceras de origen isquémico |
Country Status (7)
Country | Link |
---|---|
US (1) | US10960011B2 (es) |
EP (1) | EP3476394A4 (es) |
JP (1) | JP2019518780A (es) |
CN (1) | CN109641001A (es) |
CA (1) | CA3065893A1 (es) |
MX (1) | MX2019000006A (es) |
WO (1) | WO2017220845A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11344260B2 (en) | 2017-07-31 | 2022-05-31 | Servicio Andaluz De Salud | Predicting the risk of death or vasospasm in a patient with a subarachnoid hemorrhage |
WO2020123312A1 (en) | 2018-12-09 | 2020-06-18 | Weinberg Assa | Method to prevent and treat macular degeneration by vasodilators |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1470236A (zh) * | 2002-07-26 | 2004-01-28 | 武汉市第四医院 | 一种治疗痔疮和肛裂的多组分制剂 |
ATE376424T1 (de) * | 2003-09-18 | 2007-11-15 | Tecnimede Sociedade Tecnico Medicinal Sa | Stabile diltiazemhydrochlorid enthaltende pharmazeutische zusammensetzung zur anwendung auf der haut und verfahren zu ihrer herstellung |
CN102552260A (zh) * | 2012-01-10 | 2012-07-11 | 姚水成 | 一种治疗冻疮的药物 |
US9333209B2 (en) * | 2012-02-10 | 2016-05-10 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions for increasing hair growth |
JP2019509338A (ja) | 2016-02-23 | 2019-04-04 | セルビシオ アンダルーサ デ サルー | 治療活性が増加した抗ウイルス剤としてのピペラジン誘導体 |
ES2580508B1 (es) | 2016-04-11 | 2018-09-12 | Servicio Andaluz De Salud | Composiciones para la prevención y/o tratamiento de los trastornos por uso de alcohol. |
ES2644216B1 (es) | 2016-04-27 | 2018-09-11 | Servicio Andaluz De Salud | Derivados del indazol para el tratamiento del gammapatías monoclonales. |
ES2722774B1 (es) | 2016-08-29 | 2020-05-26 | Servicio Andaluz De Salud | Composición útil en la detección de alergia a ácido clavulánico |
ES2681118B1 (es) | 2017-02-10 | 2019-07-31 | Servicio Andaluz De Salud | Dispositivo de inmovilización para radioterapia |
-
2017
- 2017-06-23 CN CN201780052257.3A patent/CN109641001A/zh active Pending
- 2017-06-23 CA CA3065893A patent/CA3065893A1/en not_active Abandoned
- 2017-06-23 JP JP2018567607A patent/JP2019518780A/ja active Pending
- 2017-06-23 US US16/312,898 patent/US10960011B2/en active Active
- 2017-06-23 MX MX2019000006A patent/MX2019000006A/es unknown
- 2017-06-23 WO PCT/ES2017/070460 patent/WO2017220845A1/es unknown
- 2017-06-23 EP EP17814811.0A patent/EP3476394A4/en active Pending
Non-Patent Citations (7)
Title |
---|
ELSAIE M L ET AL., STRIAE DISTENSAE (STRETCH MARKS) AND DIFFERENT MODALITIES OF THERAPY: AN UPDATE, DERMATOLOGIC SURGERY, vol. 35, no. 4, 1 April 2009 (2009-04-01), New york, US, pages 563 - 573, XP002653819, ISSN: 1076-0512 * |
FERNANDEZ GARCIA M. I. ET AL.: "Efficacy and safety of topical diltiazem 2 % in anal fissure", FARMACIA HOSPITALARIA : ORGANO OFICIAL DE EXPRESION CIENTIFICA DE LA SOCIEDAD ESPANOLA DE FARMACIA HOSPITALARIA SPAIN, vol. 33, no. 2, 28 February 2009 (2009-02-28), pages 80 - 88, XP055566439, ISSN: 1130-6343 * |
JAMES P TIERNAN ET AL.: "Benign anal conditions: haemorrhoids, fissures, perianal abscess, fistula-in-ano and pilonidal sinus. Surgery medicine publishing", ABINGTON, vol. 29, no. 8, 2011, GB . Smith Frank C T, pages 382 - 386, XP028249107, ISSN: 0263-9319 * |
JONAS-OBICHERE ET AL.: "Anal Fissure", ABINGTON . / ELSEVIERIMPRINT, vol. 21, no. 7, 7 January 2003 (2003-01-07), GB . Smith Frank C T, pages 168 - 170, XP005768814, ISSN: 0263-9319 * |
NITSCHE ALEJANDRO. RAYNAUD: "digital ulcers and calcinosis in scleroderma.", REUMATOLOGIA CLINICA SPAIN, vol. 8, no. 5, 31 August 2012 (2012-08-31), pages 270 - 277, XP055446049, ISSN: 1885-1398 * |
PUCHE JOSE J. ET AL.: "Local treatment of a chronic anal fissure with diltiazem vs. nitroglycerin. A comparative study", CIRUGIA ESPANOLA SPAIN, vol. 87, no. 4, 31 March 2010 (2010-03-31), pages 224 - 230, XP055566421, ISSN: 1578-147X * |
UD-DIN S ET AL.: "Topical management of striae distensae (stretch marks): prevention and therapy of striae rubrae and albae.", JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, vol. 30, no. 2, 31 January 2016 (2016-01-31), pages 211 - 222, XP055446057, ISSN: 1468-3083 * |
Also Published As
Publication number | Publication date |
---|---|
CA3065893A1 (en) | 2017-12-28 |
MX2019000006A (es) | 2019-08-29 |
US10960011B2 (en) | 2021-03-30 |
EP3476394A1 (en) | 2019-05-01 |
JP2019518780A (ja) | 2019-07-04 |
EP3476394A4 (en) | 2020-03-11 |
US20190321372A1 (en) | 2019-10-24 |
CN109641001A (zh) | 2019-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2429443T3 (es) | Suministro transdérmico de sustancias beneficiosas efectuado mediante un entorno de fuerza iónica elevada | |
ES2456502T3 (es) | Composición que comprende PNC o PNB para un preparado externo para la piel para el tratamiento de la dermatitis | |
ES2922933T3 (es) | Composiciones que comprenden 3-sulfato de 5-colesten-3,25-diol (25HC3S) o sal farmacéuticamente aceptable del mismo y al menos un oligosacárido cíclico | |
US20100080768A1 (en) | Compositions and Methods for the Treatment of Inflammatory Dermatosis and Other Pathological Conditions of the Skin | |
JP6121561B2 (ja) | 組織再生のための組成物および方法 | |
JP6104390B2 (ja) | ミクロスフェアを含む改良された創傷治癒用組成物 | |
WO2017220845A1 (es) | Composiciones para el tratamiento de estrías y úlceras de origen isquémico | |
ES2901419T3 (es) | Medicamento tópico para lesiones de la piel y las mucosas asociadas con epidermólisis ampollosa | |
BRPI1007812B1 (pt) | Lipoatrofia cosmetic medicinal | |
CA3031678C (en) | Injectable composition for localized fat reduction without pain, edema, and side effects, and method for preparing same | |
Coskey | Contact dermatitis caused by ECG electrode jelly | |
ES2613950T3 (es) | Composiciones de Oleuropeína para cicatrización de heridas y úlceras en ancianos y/o diabéticos | |
PT2011504E (pt) | Agente dermatológico para o tratamento e/ou de cuidados da pele nos casos de dermatite atópica | |
US20110159077A1 (en) | Pentoxifilin-based dermatological pharmaceutical composition, for topical application, in cream, gel, solution, emulsion, liposome and microcapsule form | |
ES2314365T3 (es) | Utilizacion de una composicion que comprende oxido de vitamina k1 o un derivado del mismo para el tratamiento y/o la prevencion de lesiones dermatologicas en los mamiferos. | |
WO2021257027A1 (en) | An effective composition in healing wounds | |
ES2615748T3 (es) | Uso de pidotimod para tratar la dermatitis atópica | |
ES2583127T3 (es) | Aplicación transdérmica de prostaglandina E1 para el tratamiento de la isquemia ocular | |
ES2694623T3 (es) | Tratamiento o prevención de la queratosis seborreica utilizando artemisinina y derivados de la misma | |
US20190365735A1 (en) | Compositions and methods for treating varicose veins | |
EA032200B1 (ru) | Состав гепарина для наружного применения | |
RU2774074C1 (ru) | Средство для лечения диффузной фиброзно-кистозной мастопатии у кошек | |
JP2017122071A (ja) | ケロイド・肥厚性瘢痕形成抑制及び治癒促進のための経皮吸収製剤 | |
JP3187806B2 (ja) | ニトロイミダゾール系化合物を含むアトピー性皮膚炎治療用の外用剤 | |
JP3568881B2 (ja) | 皮膚疾患治療用外用剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17814811 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2018567607 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017814811 Country of ref document: EP Effective date: 20190123 |
|
ENP | Entry into the national phase |
Ref document number: 3065893 Country of ref document: CA |